Exercise-induced Glycemic Variations and Hybrid Closed-loop Systems

NCT05736263 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-04-25

No results posted yet for this study

Summary

Type 1 diabetes is characterized by high risk of hypoglycemia and associated fear of hypoglycemia. Hypoglycemia risk is higher during and after physical activity, especially aerobic activity of long duration. Fear of hypoglycemia can result in avoidance of exercise or overcompensatory eating, both related to worse metabolic control and increased cardiometabolic risk. Hybrid closed-loop (HCL)systems have significantly improved risk of hypoglycemia. They also offer the possibility to set a temporary target for physical activity, further reducing the risk of hypoglycemia during physical activity. Although temporary target seems to work rather well with moderate-intensity aerobic exercise, little data is available for other types of exercise, like resistance exercise, high-intensity interval exercise, combined modalities of exercise, in which the temporary target seems to perform less well. The present study aims to test the performance of current HCL systems under different exercise conditions and evaluate the relationship between different exercise variables (recorded during exercise), physical activity variables (measured by accelerometry) and glycemic variations in HCL system users.

Conditions

Interventions

BEHAVIORAL

Moderate intensity exercise

moderate intensity aerobic exercise trial

BEHAVIORAL

High intensity interval exercise

High intensity interval exercise trial

BEHAVIORAL

Combined exercise

Combined aerobic and resistance exercise trial

BEHAVIORAL

Resistance exercise

Resistance exercise trial

Sponsors & Collaborators

  • University of Rome Foro Italico

    collaborator OTHER
  • University of Padova

    collaborator OTHER
  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Giuseppe Pugliese · University of Roma La Sapienza

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-12-22
Completion
2024-12-22

Countries

  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05736263 on ClinicalTrials.gov